

FIRE HFpEF

<u>INVESTIGATORS</u>	<ul style="list-style-type: none">• Dinesh Sharma, MD-Principal Investigator• Viviana Navas, MD Sub Investigator• Luis Rechani, MD Sub-Investigator• Samantha Sublette, MD Sub-Investigator
<u>Trial Objective</u>	<ul style="list-style-type: none">• Determine if personalized rate pacing and tachycardia remodeling pacing can favorably remodel HFpEF patients by increasing chamber volume.• Characterize effects of acute AVNS on inflammatory markers. <p>Determine if personalized rate pacing and tachycardia remodeling pacing can improve Health Status for HFpEF patients.</p>
<u>Randomization</u>	Subjects will be randomized 1:1 for AVNS and 3:1 for personalized lower rate and tachycardia remodeling pacing. Subjects within the tachycardia remodeling and personalized lower rate pacing group will be subsequently randomized to either continue treatment or will be reprogrammed to personalized lower rate pacing only.
<u>Key Inclusion</u>	<ul style="list-style-type: none">• Diagnosis of Heart Failure LVEF $\geq 55\%$• NYHA Functional Class I-III• LV End Diastolic Volume (LVEDV) Indexed to body surface area $\leq 80 \text{ ml/m}^2$• Stable on GDMT for at least 1 month
<u>Key Exclusion</u>	<ul style="list-style-type: none">• Current permanent or persistent AF• Severe aortic valve or mitral valve disease, defined as severe regurgitation or valve area of $<1 \text{ cm}^2$• Severe pulmonary disease including severe COPD